blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1050531

EP1050531 - Pyridine and piperidine derivatives for treating neurodegenerative diseases [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.09.2005
Database last updated on 22.01.2025
Most recent event   Tooltip23.09.2005No opposition filed within time limitpublished on 09.11.2005  [2005/45]
Applicant(s)For all designated states
Les Laboratoires Servier
22, rue Garnier
92200 Neuilly sur Seine / FR
[N/P]
Former [2001/47]For all designated states
LES LABORATOIRES SERVIER
22, rue Garnier
92200 Neuilly sur Seine / FR
Former [2000/45]For all designated states
ADIR ET COMPAGNIE
1 rue Carle Hébert
92415 Courbevoie Cédex / FR
Inventor(s)01 / Meth-Cohn, Otto
10 Crofts Park, Hepscott
Morpeth, Northumberland NE61 6LJ / GB
02 / Yu, Chu-YI
132 Marlborough Road
Oxford OX1 4LS / GB
03 / Lestage, Pierre
9, Allée de la Grande Terre
78170 La Celle St. Cloud / FR
04 / Lebrun, Marie-Cécile
32 Bis Rue de l'Alma
92600 Asnières / FR
05 / Caignard, Daniel-Henri
22, Avenue de la République
78230 Le Pecq / FR
06 / Renard, Pierre
3, Avenue du Parc
78150 Le Chesnay / FR
[2000/45]
Application number, filing date00401198.702.05.2000
[2000/45]
Priority number, dateFR1999000569005.05.1999         Original published format: FR 9905690
[2000/45]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report 
No.:EP1050531
Date:08.11.2000
Language:FR
[2000/45]
Type: B1 Patent specification 
No.:EP1050531
Date:17.11.2004
Language:FR
[2004/47]
Search report(s)(Supplementary) European search report - dispatched on:EP26.06.2000
ClassificationIPC:C07D213/50, C07D213/30, C07D211/22, C07D211/32, C07D213/36, C07D401/06, A61K31/435, A61P25/28
[2000/45]
CPC:
C07D213/30 (EP,US); C07D211/00 (KR); A61P25/00 (EP);
A61P25/02 (EP); A61P25/04 (EP); A61P25/16 (EP);
A61P25/28 (EP); C07D211/22 (EP,US); C07D211/32 (EP,US);
C07D213/36 (EP,US); C07D213/50 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/45]
Extension statesAL12.05.2000
LT12.05.2000
LV12.05.2000
MK12.05.2000
RO12.05.2000
SI12.05.2000
TitleGerman:Pyridin- und Piperidinderivate zur Behandlung von neurodegenerativen Erkrankungen[2000/45]
English:Pyridine and piperidine derivatives for treating neurodegenerative diseases[2000/45]
French:Composés pyridiniques ou pipéridiniques substitués pour le traitement des maladies neurodégénératives[2000/45]
Examination procedure12.05.2000Examination requested  [2000/45]
07.08.2001Despatch of a communication from the examining division (Time limit: M06)
28.01.2002Reply to a communication from the examining division
26.07.2002Despatch of a communication from the examining division (Time limit: M04)
28.11.2002Reply to a communication from the examining division
17.04.2003Despatch of a communication from the examining division (Time limit: M04)
21.05.2003Reply to a communication from the examining division
03.06.2004Communication of intention to grant the patent
07.08.2004Fee for grant paid
07.08.2004Fee for publishing/printing paid
Opposition(s)18.08.2005No opposition filed within time limit [2005/45]
Fees paidRenewal fee
15.04.2002Renewal fee patent year 03
24.04.2003Renewal fee patent year 04
05.05.2004Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US3931155  (GRISAR J MARTIN, et al) [X] 1,2,5,7 * claim - *;
 [A]EP0336886  (CIBA GEIGY AG [CH]) [A] 1,17,18 * example 14; claim 1 *;
 [A]WO9824765  (ADIR [FR], et al) [A] 1,17,18 * the whole document *;
 [X]WO9834615  (SYNAPSE PHARMACEUTICALS INTERN [CA], et al) [X] 1,17,18 * utilisation de lobeline;; claims 18,26 *;
 JPH10287634  [ ] (OTSUKA PHARMA CO LTD);
 [X]US5830904  (CROOKS PETER A [US], et al) [X] 1,2,6-8,17 * column 5 *;
 [X]  - BUDAVARI, The Merck Index, twelfth edition, MERCK & CO., (1996), XP002139362 [X] 1,2,6-8,17 * lobeline; lobelanine; lobelanidine; page 946 - page 947 *
 [X]  - KOMIN, ANDREW P. ET AL, "The SRN1 mechanism in heteroaromatic nucleophilic substitution. Photostimulated reactions of halopyridines with ketone enolates", J. ORG. CHEM. (1977), 42(14), 2481-6, XP002129337 [X] 1 * composé 5 *

DOI:   http://dx.doi.org/10.1021/jo00434a029
 [X]  - CRABB, TREVOR A. ET AL, "Proton magnetic resonance studies of compounds with bridgehead nitrogen atoms. XII. Configurational and conformational studies with perhydrocycloalkano[e]pyrido[1,2-c][1,3]oxazines", TETRAHEDRON (1970), 26(5), 1217-33, XP002129338 [X] 1 * page 1219 *

DOI:   http://dx.doi.org/10.1016/S0040-4020(01)92990-4
 [X]  - TREIBS, "Pyridyl-(2)-alkanole und Pyridyl-(2)-äthylene", CHEMISCHE BERICHTE., VERLAG CHEMIE GMBH. WEINHEIM., DE, (1960), ISSN 0009-2940, pages 2591 - 2603, XP002139386 [X] 1 * page 2593 *
 [X]  - MCCURDY, CHRISTOPHER R. ET AL, "Chiral separation of lobeline analogs using high-performance capillary electrophoresis and derivatized cyclodextrins as chiral additives", CHEMABS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 130:231638, URL: STN, XP002139404 [X] 1,17,18 * abstract *
    [ ] - ELECTROPHORESIS (1999), 20(1), 212-218
 [X]  - MORI, TOYOKI ET AL, "Preparation of benzenes as protein kinase C inhibitors", CHEMABS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 129:343326, URL: STN, XP002139405 [X] 1,17,18 * abstract *
 [X]  - OVERTON, DONALD A., "Comparison of the degree of discriminability of various drugs using the T-maze drug discrimination paradigm", CHEMABS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 97:49706, URL: STN, XP002139406 [X] 1,17,18 * abstract *
    [ ] - PSYCHOPHARMACOLOGY (BERLIN) (1982), 76(4), 385-95
 [PX]  - FLAMMIA, "Lobeline: Structure-Affinity investigation of nicotinic acetylcholinergic receptor binding", JOURNAL OF MEDICINAL CHEMISTRY., AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, (199909), vol. 42, ISSN 0022-2623, pages 3726 - 3731, XP002139387 [PX] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm990286m
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.